Friday 6 November 2026 Export RGEN’s income statement to Excel — free account

Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue: +10.9%
EPS: −351.9%
Free cash flow: −11.5%
Total debt: +3.28%

Quarter to September 2026, against a year earlier

171.32 2.84 +1.69%

Follow RGEN

Alert me

Market cap: $10.8B
P/E: 0.0×
Fwd P/E: −615×
Dividend yield: —
F-score: 6/9
Altman Z: 7.49
Beneish M: −2.52
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Repligen Corporation 8-K filed Sep 15, 2026

Period ended Sep 10, 2026 · Filed Sep 15, 2026 · accepted 4:04 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers

Red flags

Officer departure Sep 15, 2026
Repligen Corporation reported the departure of its Chief Executive Officer

8-K filed Sep 15, 2026 · The filing · sec.gov